SYDNEY, Dec. 9, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share top-line final data from its phase I study of Cantrixil (TRX-E-002-1) in patients with persistent or recurrent ovarian cancer (NCT02903771).
Key Points
“Get your website to number one on Google.” It is an appealing sales pitch. For a business owner trying to attract custome...
Apple has started another round of anticipation with a short message pointing towards new product announcements next week. ...
Buses are the most used mode of public transport in Australia, and building replacements for the huge fleets around the cou...
A folding screen is an engineering achievement. The willingness to spend several thousand dollars ...
A Brisbane-based online marketplace is taking a different approach to buying and selling: everything...
The supermarket receipt tells only part of the story. Coffee, lunches, takeaway and dining out can...
On opposite sides of Australia, two celebrated coastal destinations face a shared challenge: maint...
The supermarket receipt tells only part of the story. Coffee, lunches, takeaway and dining out can...
On opposite sides of Australia, two celebrated coastal destinations face a shared challenge: maint...
Get ready to raise a stein, don your lederhosen and embrace the spirit of Bavaria, with Camden Val...